Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 42Tumor-Agnostic 19Thoracic 5Genitourinary 4Sarcoma 3Head & Neck 3Gynecologic 3Endocrine 2Dermatologic 2CNS 2NET 1Breast 1

Conditions

Neuroendocrine Tumors 3Vipoma 1Somatostatinoma 1Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastro-enteropancreatic neuroendocrine tumor 1Gastrinoma 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Everolimus 5Sunitinib 4lutetium Lu 177 dotatate 2PM 01183 2Octreotide 2Doxorubicin 2trifluridine tipiracil drug combination 1telotristat ethyl 1repotrectinib 1pralsetinib 1pegfilgrastim 1pasireotide 1motesanib diphosphate 1epothilone B 1dactolisib 1copper dotatate CU-64 1batifiban 1avelumab 1alectinib 1Temozolomide 1TKM-080301 1Surveys and Questionnaires 1SNX-5422 1Referral and Consultation 1Radiomics 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Molecular Diagnostic Techniques 1Lutetium-177 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Oxaliplatin × NET × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡